MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

Danielle Brazel; Misako Nagasaka

doi:10.2147/LCTT.S453974

MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

Lung Cancer (Auckl). 2024 Apr 12:15:41-47. doi: 10.2147/LCTT.S453974. eCollection 2024.

Authors

Danielle Brazel¹, Misako Nagasaka^{2

3}

Affiliations

¹ Department of Hematology/Oncology, Scripps Clinic/Scripps Green Hospital, La Jolla, CA, USA.
² Department of Hematology/Oncology, University of California Irvine School of Medicine, Chao Family Cancer Center, Orange, CA, USA.
³ Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.

Abstract

Osimertinib is the current first-line treatment for EGFR-mutated NSCLC, however, patients frequently relapse due to acquired resistance mutations. Amivantamab is a bispecific antibody against EGFR and MET alterations. Lazertinib is a tyrosine kinase inhibitor active against EGFR mutations including common resistance mutations. The MARIPOSA trial was designed to study if the combination of amivantamab plus lazertinib in untreated epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients would provide improved progression-free survival. Here, we discuss the rationale for the study and the early results of MARIPOSA.

Keywords: bispecific antibody; epidermal growth factor receptor (EGFR) mutations; first line treatment.

Grants and funding

No funding was secured for this report.